(RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults. The company noted ...

Please provide your email address to receive an email when new articles are posted on . Qulipta, an oral CGRP receptor antagonist, has been approved to prevent chronic and episodic migraine in adults.

AbbVie ABBV announced that the FDA has approved the label expansion of its migraine drug Qulipta (atogepant) at 60mg dose to include the prevention of chronic migraine in adults. Following the ...

QULIPTA blocks CGRP through a once-daily dose and is available in three strengths for the preventive treatment of episodic migraine – 10 mg, 30 mg and 60 mg. Only the 60 mg dose of QULIPTA is ...

Qulipta is a brand-name oral tablet that prevents occasional and chronic migraine episodes. Common side effects include nausea, constipation, and fatigue. Most side effects from Qulipta are mild.

AbbVie’s Qulipta has gained an edge in the heated migraine market thanks to a new approval to prevent chronic migraines. The new FDA nod makes the pill the only oral calcitonin gene-related peptide ...

Qulipta (atogepant), a medication approved in the U.S. for the prevention of episodic migraine, has now been approved for chronic migraine prevention, too. Qulipta’s maker, AbbVie, announced the ...